It is the first reported case of death after a coronavirus vaccination in Japan. The woman, in her 60s and with no pre-existing condition, is believed to have died of subarachnoid hemorrhage, the ministry said, weeks after Japan launched the first phase of its vaccination program.
woman who received Pfizer's coronavirus vaccine has died, but so far there has been no link found between her death and the inoculation, the health ministry said Tuesday.
It is the first reported case of death after a coronavirus vaccination in Japan. The woman, in her 60s and with no pre-existing condition, is believed to have died of subarachnoid hemorrhage, the ministry said, weeks after Japan launched the first phase of its vaccination program.
The ministry said at the moment it has not determined whether the woman's death on Monday came as a result of her having been administered the vaccine. Health authorities were notified of the death on Tuesday.
The ministry has not revealed details such as where the woman lived.
Tomohiro Morio of a working panel on vaccines under the ministry said that based on inoculation cases abroad, there appears to be no connection between the COVID-19 vaccination and subarachnoid hemorrhage.
The ministry said the woman received the vaccine on Friday and that she did not suffer from any allergy.
Japan began its COVID-19 vaccinations on Feb. 17 for an initial group of 40,000 health workers at 100 hospitals nationwide. Senior citizens are expected to get shots from April 12, followed by those with pre-existing conditions, such as diabetes, and workers at elderly care facilities, and then finally the general population.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.
Quickly share this news with your network—keep everyone informed with just a single click!
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!